Greenwich LifeSciences Leadership Extends Share Lock-Up Through 2026, Signaling Confidence in Clinical Trials

Stafford, Monday, 29 December 2025.
Directors voluntarily extended share restrictions through September 2026. This unprecedented six-year lock-up underscores strong insider confidence in the FLAMINGO-01 breast cancer trial’s potential.